TY - JOUR
T1 - The tumorsusceptibilitygene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function
AU - Qin, Y.
AU - Deng, Y.
AU - Ricketts, C. J.
AU - Srikantan, S.
AU - Wang, E.
AU - Maher, E. R.
AU - Dahia, P. L.M.
N1 - Funding Information:
This study was supported by grants from the Cancer Prevention and Research Institute of Texas (CPRIT #RP110202), Department of Defense CDMRP (#W81XWH-12-1-0508), Voelcker Fund, Alex’s Lemonade Foundation, Concern Foundation and Greehey Children’s Cancer Research Institute (GCCRI) to P.L.M.D. Images were generated in the Core Optical Imaging Facility which is supported by UTHSCSA, NIH-NCI P30 CA54174 (CTRC at UTHSCSA) and NIH-NIA P01AG19316.
PY - 2014/5
Y1 - 2014/5
N2 - TMEM127 is an endosome-associated tumor suppressor gene in pheochromocytomas, neuroendocrine tumors that can co-occur with renal cell carcinomas (RCCs). TMEM127 loss leads to increased mTOR signaling. However, the spectrum of tumors with TMEM127 mutation and how TMEM127 and mTOR interact in tumorigenesis remains unknown. Here, we report that germline TMEM127 mutations occur in RCCs and that somemutant proteins, unlike wild-type (WT) TMEM127, fail to cooperate with activated early endosomal GTPase, Rab5, to inhibit mTOR signaling. Tmem127-null mouse embryonic fibroblasts (MEFs) are deficient in generating earlyto- late hybrid endosomes upon constitutive Rab5 activation, a defect rescued by WT, but not mutant, TMEM127. This endosomal dysfunction results in diminishedmTORcolocalization with Rab5-positive vesicles. Conversely, active, lysosomal-bound mTOR is increased in Tmem127-null MEFs, which also display enhanced lysosomal biogenesis. Our data map the tumor-suppressive properties of TMEM127 to modulation of mTOR function in the endolysosome, a feature thatmaycontribute to bothpheochromocytomaandRCCpathogenesis.
AB - TMEM127 is an endosome-associated tumor suppressor gene in pheochromocytomas, neuroendocrine tumors that can co-occur with renal cell carcinomas (RCCs). TMEM127 loss leads to increased mTOR signaling. However, the spectrum of tumors with TMEM127 mutation and how TMEM127 and mTOR interact in tumorigenesis remains unknown. Here, we report that germline TMEM127 mutations occur in RCCs and that somemutant proteins, unlike wild-type (WT) TMEM127, fail to cooperate with activated early endosomal GTPase, Rab5, to inhibit mTOR signaling. Tmem127-null mouse embryonic fibroblasts (MEFs) are deficient in generating earlyto- late hybrid endosomes upon constitutive Rab5 activation, a defect rescued by WT, but not mutant, TMEM127. This endosomal dysfunction results in diminishedmTORcolocalization with Rab5-positive vesicles. Conversely, active, lysosomal-bound mTOR is increased in Tmem127-null MEFs, which also display enhanced lysosomal biogenesis. Our data map the tumor-suppressive properties of TMEM127 to modulation of mTOR function in the endolysosome, a feature thatmaycontribute to bothpheochromocytomaandRCCpathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84897504141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897504141&partnerID=8YFLogxK
U2 - 10.1093/hmg/ddt638
DO - 10.1093/hmg/ddt638
M3 - Article
C2 - 24334765
AN - SCOPUS:84897504141
SN - 0964-6906
VL - 23
SP - 2428
EP - 2439
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 9
M1 - ddt638
ER -